Vielen Dank für Ihre Anfrage.
Wir werden Sie innerhalb weniger Werktage kontaktieren.
(Geschäftseinheit Performance Materials, Sales Support Team)
Gebäude AIA Central, Ebene 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesien
+62 21 2988 8557
Erfolg! Ihre Anfrage wurde an unser Vertriebsteam übermittelt.
Etwas ist schiefgelaufen! Bitte versuchen Sie es später erneut.
Wir haben 16 Elemente gefunden.
| Kontaktdaten des Antragstellers | |
| Vollständiger Name | |
| Unternehmen | |
| Position | |
| Telefonnummer | |
| Geschäftliche E-Mail-Adresse | |
| Lieferadresse | |
Thank you. Your request has been sent.
Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Dexmedetomidine Hydrochloride (HCl) stands as a pivotal chemical for the pharmaceutical sector, utilized primarily as a sedative, anxiolytic, and analgesic agent. Under the umbrella of performance materials, this product maintains a strong presence within medical settings, with a focus on providing sedation for non-intubated patients before and/or during surgical and other procedures. It's also used in intensive care sedation for intubated, mechanically ventilated patients. Manufactured in adherence to stringent standards, Dexmedetomidine HCl is a white or almost white powder that dissolves freely in DMSO and is slightly soluble in methanol and water, ensuring its ease of adoption in various pharmaceutical formulations. Our product complies with the United States Drug Master File (US DMF), and proudly carries the European Union Good Manufacturing Practice (EU GMP) certification, attesting to its high-grade quality and the thoroughness of its production process. Beyond its uses, this product is defined by its anatomical therapeutic chemical classification, which refers to a system used for the classification of drugs. A prime focus is on organic purity, with individual impurities like Dimethylphenylethyl imidazole and Levomedetomidine meticulously controlled to exceed pharmacopeial standards. Our product boasts a laudable enantiomeric purity and an assay value ranging between 98.0% and 102.0%, exemplifying its consistency and reliability. It is vital to note that our Dexmedetomidine HCl maintains permissible thresholds for residual solvents, ensuring the safety and efficacy of the drug. The list of related substances and required specifications for solvents like acetone, ethanol, and benzene are rigorously quantified below recognized safety limits, aligning with the highest regulatory expectations. We ensure that each batch is synonymous with excellence, a testament to our unwavering commitment to the highest quality standards in pharmaceutical ingredients. By choosing our Dexmedetomidine HCl, stakeholders in the pharmaceutical industry can confidently incorporate a product that is not only potent and versatile but also conforms to the critical parameters of drug safety and manufacturing excellence. For more information, please visit our website or contact our customer service team, who stand ready to assist with product inquiries and logistic details.
Products still subject to third-party patent protection might be available solely for R&D purposes.
Refarmed Chemicals presents Ciprofibrate, a crucial pharmaceutical material developed for clinical efficacy in managing lipid disorders. Developed with the utmost precision, Ciprofibrate is a fibrate-class drug specially formulated as a therapeutic agent to regulate high levels of cholesterol and triglycerides, factors leading to cardiovascular diseases. Our product is synthesized with rigorous compliance to quality standards, evidenced by its Good Manufacturing Practice (GMP) certification. The drug appears as a white or slightly yellow-white crystalline powder, indicative of its purity. Highly soluble in anhydrous ethanol and toluene yet practically insoluble in water, Ciprofibrate facilitates flexibility in pharmaceutical formulation, allowing for both tablet and capsule dosage forms in strengths of 100mg and 200mg. Targeting primary hypercholesterolemia (type IIa or IIb), mixed dyslipidemia, and as preventive treatment against cardiovascular events in high cholesterol patients, Ciprofibrate's composition facilitates the acceleration of cholesterol and triglyceride breakdown and removal from the body. Recommended for bi-daily intake alongside meals, the treatment's efficacy is augmented by adherence to healthy lifestyle choices, including a balanced diet and regular exercise. Safety parameters dictate careful administration especially to those with a history of gallbladder disease, and periodic liver function evaluations are advised. Contraindications include severe renal or hepatic conditions, pregnancy, breastfeeding, or known hypersensitivity to fibrates. Consultation with healthcare professionals is critical when concomitant medications are involved, particularly statins, anticoagulants, and antibiotics. Storage requirements for Ciprofibrate are straightforward — room temperature conditions away from light and moisture ensure stability. As a product from the storied catalogue of Refarmed Chemicals, now part of the DKSH Group, Ciprofibrate is accompanied by dependable documentation for Detailed and Master Files, affirming its reputable standard in pharmaceutical resources.
Products still subject to third-party patent protection might be available solely for R&D purposes.
**Product Overview: Febuxostat – A Robust Solution for Gout Management** Refarmed Chemicals presents Febuxostat, a meticulously prepared medication aimed at alleviating the pain and discomfort associated with gout. Made from a refined white powder, Febuxostat stands out in the pharmaceutical industry as a Xanthine Oxidase Inhibitor, crucial for managing hyperuricemia and recurrent gout attacks. Structured to meet corporate expectations, Febuxostat is a testament to Refarmed Chemicals' 30-year expertise in delivering quality generic and branded medications. Manufactured in compliance with strict guidelines, including the Drug Master File (DMF) and certifications such as WC and GMP, this product is a model of reliability and efficacy. Febuxostat's fundamental use is to decrease blood uric acid levels, offering those afflicted with gout a pathway to recovery by preventing acute flare-ups, and mitigating inflammation and pain in the joints. As a white, soluble powder, Febuxostat is highly soluble in DMSO and slightly soluble in methanol and water, simplifying its integration into diverse medical formulations. Clinical trials have informed a standard starting dosage of 40 mg, adjustable up to 80 mg based on individual patient requirements and the severity of symptoms. In its commitment to patient welfare, Refarmed Chemicals underlines potential side effects ranging from nausea and headaches to rashes, ensuring informed usage of Febuxostat. In alignment with our promise of transparency and safety, we advise consulting healthcare professionals for precise diagnotics and treatment plans. Furthermore, users should be attentive to contraindications, noting that Febuxostat is unsuitable for patients with severe liver or kidney disease, or for women who are pregnant or breastfeeding. Refarmed Chemicals' Febuxostat exceeds industry standards with its impressive assay value of 98.0% - 102.0% purity and a precise control of impurities, ensuring that the product meets stringent quality criteria. The company's analytical rigor is reflected in the detailed specification of residual solvents such as Acetone, Ethanol, and Isopropanol. In the journey to deliver improved health outcomes, Refarmed Chemicals' Febuxostat is more than just a medication; it symbolizes our dedication to quality, safety, and corporate responsibility in the global pharmaceutical landscape. [*Note: Product image depicts a detailed specification chart for Febuxostat, reiterating its quality and compositions.*]
Products still subject to third-party patent protection might be available solely for R&D purposes.